Frank Holler
Chairman bei THERATECHNOLOGIES INC.
Vermögen: 617 097 $ am 31.03.2024
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Ian Mortimer | M | 48 | 11 Jahre | |
Michael Hayden | M | 72 |
University of British Columbia
| 41 Jahre |
Simon Pimstone | M | 56 | 28 Jahre | |
Dawn Svoronos | F | 70 | 11 Jahre | |
Gord Davey | M | - | 6 Jahre | |
Andy Bayfield | M | - | 5 Jahre | |
Mohammad Azab | M | 68 | 21 Jahre | |
Paul Lévesque | M | 60 | 4 Jahre | |
Jack Tasse | M | - | 4 Jahre | |
Jocelyn Lafond | M | 56 | 17 Jahre | |
Philippe Dubuc | M | 57 | 8 Jahre | |
Brett Whalen | M | - | 1 Jahre | |
Jodi Regts | F | - | 9 Jahre | |
Andrew Molson | M | 56 | 4 Jahre | |
Frank Shannon | M | - | 3 Jahre | |
Marie-Noël Colussi | F | 55 | 27 Jahre | |
Clarence Machado | M | 60 | 4 Jahre | |
Sherry Aulin | F | 40 | 13 Jahre | |
Jason Bednar | M | 52 | 7 Jahre | |
Joseph Arena | M | 69 | 3 Jahre | |
Steven Gannon | M | 62 | 9 Jahre | |
R. Bustin | M | - |
University of British Columbia
| 47 Jahre |
Gary Patou | M | 65 | 20 Jahre | |
Dale MacCandlish-Weil | F | 68 | 7 Jahre | |
Dale Weil | M | - | 1 Jahre | |
John Leasure | M | - | 3 Jahre | |
Peter Kowal | M | - | 3 Jahre | |
Steven Sangha | M | - | 1 Jahre | |
Chris von Seggern | M | - | 4 Jahre | |
André Dupras | M | 60 | 3 Jahre | |
Ambrose Hong | M | - |
BC Advantage Funds Ltd.
BC Advantage Funds Ltd. Investment ManagersFinance Founded 2003, BC Advantage Funds (VCC) Ltd is a venture capital firm, headquartered in Canada. | - |
Orit Segev | M | - |
Genome British Columbia
Genome British Columbia Miscellaneous Commercial ServicesCommercial Services Genome British Columbia invests in and manages genomics and proteomics research projects. It offers services in human health, environment, agriculture, forestry, mining, energy, aquaculture, and fisheries. The company was founded in 2000 and is headquartered in Vancouver, Canada. | 15 Jahre |
Ágnes Baross | M | - |
Genome British Columbia
Genome British Columbia Miscellaneous Commercial ServicesCommercial Services Genome British Columbia invests in and manages genomics and proteomics research projects. It offers services in human health, environment, agriculture, forestry, mining, energy, aquaculture, and fisheries. The company was founded in 2000 and is headquartered in Vancouver, Canada. | 17 Jahre |
Patricia Lee | F | - |
Genome British Columbia
Genome British Columbia Miscellaneous Commercial ServicesCommercial Services Genome British Columbia invests in and manages genomics and proteomics research projects. It offers services in human health, environment, agriculture, forestry, mining, energy, aquaculture, and fisheries. The company was founded in 2000 and is headquartered in Vancouver, Canada. | 16 Jahre |
Robin Sherrington | M | 63 | 23 Jahre | |
Christian Marsolais | M | 61 | 17 Jahre | |
Shelley McCloskey | F | 64 | 5 Jahre | |
Sheila M. Grant | F | - | 4 Jahre | |
David P. Charest | M | - |
Genome British Columbia
Genome British Columbia Miscellaneous Commercial ServicesCommercial Services Genome British Columbia invests in and manages genomics and proteomics research projects. It offers services in human health, environment, agriculture, forestry, mining, energy, aquaculture, and fisheries. The company was founded in 2000 and is headquartered in Vancouver, Canada. | 19 Jahre |
Raymond J. Andersen | M | 76 |
University of British Columbia
| 47 Jahre |
Daniel Mahony | M | - | 2 Jahre | |
Julie Schneiderman | F | - | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
David Hall | M | 71 |
Angiotech Pharmaceuticals, Inc.
Angiotech Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company, which engages in developing, manufacturing and marketing medical products and technologies, within the areas of interventional oncology, wound closure and ophthalmology. The company was founded by William L. Hunter and Cruz F. Tony in 1992 and is headquartered in Vancouver, Canada. | 14 Jahre |
Tony Holler | M | 72 |
ID Biomedical Corp.
ID Biomedical Corp. Medical SpecialtiesHealth Technology ID Biomedical Corp. develops gene-based disease testing and subunit vaccines. It conducts research, development, manufacturing, sales, and marketing from its facilities in Canada and in the United States. The company was founded in 1991 and is headquartered in Vancouver, Canada.
University of British Columbia
| 18 Jahre |
Gordon McCauley | M | - | 9 Jahre | |
Lars Ekman | M | 74 | 10 Jahre | |
Leonard J. Cox | M | 52 | 2 Jahre | |
Gary Bridger | M | 61 |
Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops targeted therapeutics for inflammation and immuno-oncology. It also focuses on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. The company was founded by Raymond J. Andersen, David J. Main, Low Fung Mui, Christopher John Ong, and Gerald Krystal on December 26, 2003 and is headquartered in Vancouver, Canada. | 6 Jahre |
David Swetlow | M | - | 8 Jahre | |
Ian M. Mallmann | M | 63 |
University of British Columbia
| 11 Jahre |
Todd R. Patrick | M | 61 |
ID Biomedical Corp.
ID Biomedical Corp. Medical SpecialtiesHealth Technology ID Biomedical Corp. develops gene-based disease testing and subunit vaccines. It conducts research, development, manufacturing, sales, and marketing from its facilities in Canada and in the United States. The company was founded in 1991 and is headquartered in Vancouver, Canada. | 11 Jahre |
Antonio F. Cruz | M | 71 |
Angiotech Pharmaceuticals, Inc.
Angiotech Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company, which engages in developing, manufacturing and marketing medical products and technologies, within the areas of interventional oncology, wound closure and ophthalmology. The company was founded by William L. Hunter and Cruz F. Tony in 1992 and is headquartered in Vancouver, Canada. | - |
Allison Hulme | M | 61 | - | |
Bill Hunter | M | 61 |
Angiotech Pharmaceuticals, Inc.
Angiotech Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company, which engages in developing, manufacturing and marketing medical products and technologies, within the areas of interventional oncology, wound closure and ophthalmology. The company was founded by William L. Hunter and Cruz F. Tony in 1992 and is headquartered in Vancouver, Canada. | 19 Jahre |
Evan Stein | M | 77 | 8 Jahre | |
Kamran Alam | M | 50 |
Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops targeted therapeutics for inflammation and immuno-oncology. It also focuses on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. The company was founded by Raymond J. Andersen, David J. Main, Low Fung Mui, Christopher John Ong, and Gerald Krystal on December 26, 2003 and is headquartered in Vancouver, Canada. | 8 Jahre |
Terry Hamilton | M | 61 |
University of British Columbia
| 5 Jahre |
Aaron Wong | M | - | 3 Jahre | |
John E. Stonier | M | - |
University of British Columbia
| 8 Jahre |
Clarissa Desjardins | M | 57 | - | |
Andrew Kain | M | - | 2 Jahre | |
Nick Maltchev | M | - | 2 Jahre | |
Kwong Choo | M | - | - | |
J. Basil Peters | M | - |
University of British Columbia
| 8 Jahre |
Grant Froese | M | 62 | 2 Jahre | |
Michael Joseph Palazzi | M | - |
CIBC World Markets Corp. (Old)
CIBC World Markets Corp. (Old) Financial ConglomeratesFinance CIBC World Markets is a full-service investment bank headquartered in New York City. CIBC provides an internationally integrated research product through three primary strategies. In the US, the firm provides research coverage available in areas of focus, including technology, telecommunications, healthcare, energy, power generation and technology, financial institutions, consumer growth, real estate and media. In Canada, the firm offers the full spectrum of coverage for all of the sectors that form the TSE 300 Index. Their broad investment grade analysis of return bond Indices provides daily performance of the Canadian bond market. The sectors covered are: government of Canada bonds, provincial and municipal bonds and corporate bonds rated AAA/AA, A and BBB. Also available is a monthly ABS/MBS market report that provides information on ABS market conditions, market summary data and monthly performance reports on outstanding transactions. This report includes information about the MBS market, including key statistics on MBS spreads and prepayments. Another report contains MBS trading data, cash flows and other key data. A separate monthly Portfolio Valuation Report provides month end pricing for ABS and MBS transactions. Corporate debt research produces highly targeted credit analysis and research for investment grade and high yield debt securities. The corporate bond review covers bond market action, new issues, price/yield movements, rating changes, and buy/sell recommendations. The fixed-income research group produces actionable fundamental and technical analysis, strategies, products, and runs bond indexes and quantitative models relating specifically to fixed income markets, bond portfolios, and individual securities. CIBC provides risk management solutions to corporations, investors, financial institutions, and governments across all asset classes: interest rates, equities, credit, currency, and commodities. CIBC World Markets is a subsidiary of Canadian Imperial Bank of Commerce. | 16 Jahre |
Michael Edward O'Connor | M | - |
University of British Columbia
| 4 Jahre |
Mary Garden | F | 65 |
University of British Columbia
| 6 Jahre |
Chun Ning Shih | M | 60 |
University of British Columbia
| 6 Jahre |
Martin MacLachlan | M | - |
University of British Columbia
| 5 Jahre |
David Nairne | M | - |
University of British Columbia
| 5 Jahre |
Bruce A. Weber | M | - | 7 Jahre | |
Peter Wall | M | 48 | 3 Jahre | |
Robert W. R. Bishop | M | - |
University of British Columbia
| 7 Jahre |
Debra Milimaka Miles | F | - | - | |
Gregory Burnett | M | - |
University of British Columbia
| 6 Jahre |
Kenneth R. Burgess | M | - |
University of British Columbia
| 5 Jahre |
Todd Simpson | M | 63 |
Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops targeted therapeutics for inflammation and immuno-oncology. It also focuses on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. The company was founded by Raymond J. Andersen, David J. Main, Low Fung Mui, Christopher John Ong, and Gerald Krystal on December 26, 2003 and is headquartered in Vancouver, Canada. | - |
Robert E. Pelzer | M | 70 |
Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops targeted therapeutics for inflammation and immuno-oncology. It also focuses on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. The company was founded by Raymond J. Andersen, David J. Main, Low Fung Mui, Christopher John Ong, and Gerald Krystal on December 26, 2003 and is headquartered in Vancouver, Canada. | 6 Jahre |
Jeffrey Bacha | M | 56 | 14 Jahre | |
William R. Rohn | M | 80 | 3 Jahre | |
Ronald Tysoe | M | 71 |
University of British Columbia
| 5 Jahre |
Jonathan Leff | M | 55 | 2 Jahre | |
Michael M. Tarnow | M | 79 | 22 Jahre | |
Gregg Saretsky | M | 64 |
University of British Columbia
| 6 Jahre |
P. Reifel | M | 72 |
University of British Columbia
| 6 Jahre |
Gary Littlejohn | M | 68 | 5 Jahre | |
S. Simpson | M | 67 |
University of British Columbia
| 7 Jahre |
Malcolm J. P. Finlayson | M | - |
University of British Columbia
| 7 Jahre |
Steven Nizam Khan | M | - |
University of British Columbia
| 7 Jahre |
Paul Bowes | M | - |
University of British Columbia
| 4 Jahre |
Jack H. L. Miller | M | - |
University of British Columbia
| 6 Jahre |
Elaine Jones | M | 69 |
Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops targeted therapeutics for inflammation and immuno-oncology. It also focuses on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. The company was founded by Raymond J. Andersen, David J. Main, Low Fung Mui, Christopher John Ong, and Gerald Krystal on December 26, 2003 and is headquartered in Vancouver, Canada. | 5 Jahre |
R. MacKay-Dunn | M | 73 |
Genome British Columbia
Genome British Columbia Miscellaneous Commercial ServicesCommercial Services Genome British Columbia invests in and manages genomics and proteomics research projects. It offers services in human health, environment, agriculture, forestry, mining, energy, aquaculture, and fisheries. The company was founded in 2000 and is headquartered in Vancouver, Canada. | 6 Jahre |
David de Witt | M | 71 |
University of British Columbia
| 7 Jahre |
Suzanne Wood | F | 67 |
University of British Columbia
| 6 Jahre |
Richard George Whatley | M | - |
University of British Columbia
| 9 Jahre |
David Alan Goodkin | M | - | - | |
Gérald A. Lacoste | M | 80 | 18 Jahre | |
Alain Trudeau | M | 64 | 4 Jahre |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Kanada | 94 | 94,00% |
Vereinigte Staaten | 7 | 7,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Frank Holler
- Persönliches Netzwerk